Category: News articles
- Prolight Diagnostics
A collaborative research project between Prolight and St Thomas’ Hospital has demonstrated how quickly a cardiac biomarker assay for cMyC, can be transferred onto the Psyros™ point-of-care (POC) system. The study underscores the platform’s potential and its broader diagnostic applications beyond high-sensitive troponin.
- Akershus hjerteundersøkelse 1950
På lik linje med troponin, som er forsket på i ACE 1950 tidligere, er cardiac Myosin binding protein C (cMyC) et protein i hjertemuskelen. Det er høyere konsentrasjoner av cMyC enn av troponin i hjertet og cMyC slippes tidligere ut i blodstrømmen ved akutt hjerteskade, som for eksempel ved et hjerteinfarkt. Dette gjør at måling av cMyC i blodet kan gi mulighet til å oppdage kronisk hjerteskade og arrdannelse i hjertet lenge før det utvikler seg til hjertesykdom.
- Leo O'Connor
King's College London researchers are developing a point-of-care blood test to diagnose heart attacks that uses cardiac myosin-binding protein C as an alternative biomarker to high-sensitivity troponin used in laboratory testing.
- Ben Spencer
The cMyC test correctly excluded a heart attack in 32 per cent of patients.
It could mean thousands of patients are given the all-clear and sent home within quarter of an hour of arriving at A&E. Resulting in cost savings for healthcare.
- BBC
Switching to cMyC from hs-cTn at King's College London, would yearly save the hospital £800,000 through reduced admissions.
- Kings College London
Research related to heart attacks shows that the cMyC test has the potential to reassure many thousands more patients with a single test, freeing up valuable hospital beds in ED / A&E.